548 related articles for article (PubMed ID: 26670179)
1. Register-Based Evaluation of Relative Effectiveness of New Therapies: Biologics Versus Conventional Agents in Treatment of Psoriasis in Sweden.
Norlin JM; Carlsson KS; Persson U; Schmitt-Egenolf M
BioDrugs; 2015 Dec; 29(6):389-98. PubMed ID: 26670179
[TBL] [Abstract][Full Text] [Related]
2. Sustained Psoriasis Area and Severity Index, Dermatology Life Quality Index and EuroQol-5D response of biological treatment in psoriasis: 10 years of real-world data in the Swedish National Psoriasis Register.
Hjalte F; Carlsson KS; Schmitt-Egenolf M
Br J Dermatol; 2018 Jan; 178(1):245-252. PubMed ID: 28644904
[TBL] [Abstract][Full Text] [Related]
3. Switch to biological agent in psoriasis significantly improved clinical and patient-reported outcomes in real-world practice.
Norlin JM; Steen Carlsson K; Persson U; Schmitt-Egenolf M
Dermatology; 2012; 225(4):326-32. PubMed ID: 23328678
[TBL] [Abstract][Full Text] [Related]
4. Cost effectiveness of biologic therapies for plaque psoriasis.
Ahn CS; Gustafson CJ; Sandoval LF; Davis SA; Feldman SR
Am J Clin Dermatol; 2013 Aug; 14(4):315-26. PubMed ID: 23696234
[TBL] [Abstract][Full Text] [Related]
5. Healthcare Provider Type and Switch to Biologics in Psoriasis: Evidence from Real-World Practice.
Calara PS; Norlin JM; Althin R; Carlsson KS; Schmitt-Egenolf M
BioDrugs; 2016 Apr; 30(2):145-51. PubMed ID: 26883786
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials.
Reich K; Burden AD; Eaton JN; Hawkins NS
Br J Dermatol; 2012 Jan; 166(1):179-88. PubMed ID: 21910698
[TBL] [Abstract][Full Text] [Related]
7. Biologic and Conventional Systemic Therapies Show Similar Safety and Efficacy in Elderly and Adult Patients With Moderate to Severe Psoriasis.
Garber C; Plotnikova N; Au SC; Sorensen EP; Gottlieb A
J Drugs Dermatol; 2015 Aug; 14(8):846-52. PubMed ID: 26267729
[TBL] [Abstract][Full Text] [Related]
8. Adalimumab in the treatment of moderate-to-severe chronic plaque psoriasis in patients switching from other biologics.
Sator P; Richter L; Saxinger W; Vasiljevic M; Stingl G
J Eur Acad Dermatol Venereol; 2015 Sep; 29(9):1742-9. PubMed ID: 25665143
[TBL] [Abstract][Full Text] [Related]
9. Analysis of three outcome measures in moderate to severe psoriasis: a registry-based study of 2450 patients.
Norlin JM; Steen Carlsson K; Persson U; Schmitt-Egenolf M
Br J Dermatol; 2012 Apr; 166(4):797-802. PubMed ID: 22182212
[TBL] [Abstract][Full Text] [Related]
10. Superiority in Quality of Life Improvement of Biologics over Conventional Systemic Drugs in a Swiss Real-Life Psoriasis Registry.
Jungo P; Maul JT; Djamei V; von Felten S; Kolios AGA; Czernielewsk J; Yawalkar N; Odermatt O; Laffitte E; Anliker M; Streit M; Augustin M; Conrad C; Hafner J; Boehncke WH; Gilliet M; Itin P; French LE; Navarini AA; Häusermann P
Dermatology; 2016; 232(6):655-663. PubMed ID: 28103601
[TBL] [Abstract][Full Text] [Related]
11. Real-world outcomes in 2646 psoriasis patients: one in five has PASI ≥10 and/or DLQI ≥10 under ongoing systemic therapy.
Norlin JM; Calara PS; Persson U; Schmitt-Egenolf M
J Dermatolog Treat; 2017 Sep; 28(6):500-504. PubMed ID: 28132580
[TBL] [Abstract][Full Text] [Related]
12. Durable dermatology life quality index improvements in patients on biologics associated with psoriasis areas and severity index: a longitudinal study.
Chaptini C; Quinn S; Marshman G
Australas J Dermatol; 2016 Aug; 57(3):e72-5. PubMed ID: 26010650
[TBL] [Abstract][Full Text] [Related]
13. Utility of the Dermatology Life Quality Index at initiation or switching of biologics in real-life Japanese patients with plaque psoriasis: Results from the ProLOGUE study.
Imafuku S; Kanai Y; Murotani K; Nomura T; Ito K; Ohata C; Yamazaki F; Miyagi T; Takahashi H; Okubo Y; Saeki H; Honma M; Tada Y; Mabuchi T; Higashiyama M; Kobayashi S; Hashimoto Y; Seishima M; Kakuma T
J Dermatol Sci; 2021 Mar; 101(3):185-193. PubMed ID: 33495058
[TBL] [Abstract][Full Text] [Related]
14. The effect of weight reduction on treatment outcomes in obese patients with psoriasis on biologic therapy: a randomized controlled prospective trial.
Al-Mutairi N; Nour T
Expert Opin Biol Ther; 2014 Jun; 14(6):749-56. PubMed ID: 24661040
[TBL] [Abstract][Full Text] [Related]
15. Complete skin clearance and Psoriasis Area and Severity Index response rates in clinical practice: predictors, health-related quality of life improvements and implications for treatment goals.
Norlin JM; Nilsson K; Persson U; Schmitt-Egenolf M
Br J Dermatol; 2020 Apr; 182(4):965-973. PubMed ID: 31325318
[TBL] [Abstract][Full Text] [Related]
16. German psoriasis registry PsoBest: objectives, methodology and baseline data.
Augustin M; Spehr C; Radtke MA; Boehncke WH; Luger T; Mrowietz U; Reusch M; Strömer K; Wozel G; von Kiedrowski R; Rustenbach SJ; Purwins S; Reich K
J Dtsch Dermatol Ges; 2014 Jan; 12(1):48-57. PubMed ID: 24393314
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Survival of Systemic Psoriasis Treatments: An Analysis of the Swiss Registry SDNTT.
Maul JT; Djamei V; Kolios AGA; Meier B; Czernielewski J; Jungo P; Yawalkar N; Mainetti C; Laffitte E; Spehr C; Anliker M; Streit M; Augustin M; Rustenbach S; Conrad C; Hafner J; Boehncke WH; Borradori L; Gilliet M; Itin P; French LE; Häusermann P; Navarini AA
Dermatology; 2016; 232(6):640-647. PubMed ID: 28076860
[TBL] [Abstract][Full Text] [Related]
18. Effect of infliximab on health-related quality of life and disease activity by body region in patients with moderate-to-severe psoriasis and inadequate response to etanercept: results from the PSUNRISE trial.
Kalb RE; Blauvelt A; Sofen HL; Chevrier M; Amato D; Calabro S; Wang J; Schenkel B; Gottlieb AB
J Drugs Dermatol; 2013 Aug; 12(8):874-80. PubMed ID: 23986160
[TBL] [Abstract][Full Text] [Related]
19. Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR]).
Strober BE; Bissonnette R; Fiorentino D; Kimball AB; Naldi L; Shear NH; Goyal K; Fakharzadeh S; Calabro S; Langholff W; You Y; Galindo C; Lee S; Lebwohl MG
J Am Acad Dermatol; 2016 May; 74(5):851-61.e4. PubMed ID: 26853180
[TBL] [Abstract][Full Text] [Related]
20. On clinical thresholds, clinical equivalents and indirect comparisons of biological treatments for moderate-to-severe psoriasis.
Puig L
J Clin Pharm Ther; 2015 Apr; 40(2):131-4. PubMed ID: 25627250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
